Qubigen Unlocks Second Tranche of Pre-Seed Investment Ahead of Schedule Following Advanced Results with Federated AI Drug Design

Qubigen is excited to announce that it has unlocked the second tranche of pre-seed investment from SYNthesis BioVentures ahead of schedule, following the successful application of its Federated AI platform to real-world drug development for its first client.

In its initial client engagements, Qubigen’s platform demonstrated compelling results that exceeded expectations. By integrating partner datasets with its proprietary algorithms and curated dataset, Qubigen generated AI-designed molecules with properties equal to or better than current trial-stage drugs, but in a shorter timeframe and at a lower cost. This achievement validated Qubigen’s approach of decentralised, privacy-preserving AI for accelerating early-stage drug design.

Among the most promising outcomes was the design of a novel, potentially patentable compound exhibiting a complex structure with a similar binding profile to a molecule under commercial development by a major pharmaceutical company. Notably, the Qubigen-designed compound also showed a favourable drug profile, positioning it as a strong candidate for preclinical development.

Qubigen also successfully replicated a blind holdback dataset from one of its clients, identifying 27 out of 27 molecules which had been selected for preclinical development using traditional SAR methods. In addition, its algorithms proposed 11 novel compounds with similar or improved physicochemical and ADMET properties, a strong testament to the predictive strength and real-world relevance of the AI platform.

The platform’s ability to filter active from inactive molecules also demonstrated a 6-fold enrichment from an already refined compound library, significantly enhancing hit rates and project efficiency.

These results triggered the early release of the second funding tranche from SYNthesis BioVentures, providing Qubigen with additional runway to expand its work and prepare for a Series A round in late 2025.

As Qubigen continues to develop and scale its technology, it remains committed to redefining the future of drug design through federated, ethical, and intelligent AI solutions.

Qubigen - accelerate drug design without exposing secrets.

Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next discovery.

enquiries@qubigen.com.